natgillin/translations-raw huggingface dataset:
Manufacturers responsible for batch release: 
Izdelovalec, odgovoren za sproščanje serij
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (http://www.ema.europa.eu)
Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate. 
(to je 10 ml/100 kg telesne mase), po potrebi v kombinaciji z antibiotičnim zdravljenjem ali s peroralno rehidracijsko terapijo.
Inflacam 330 mg granules for horses. 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Inflacam 330 mg zrnca za konje.
Cardboard box containing 1 colourless glass injection vial of 20 ml, 50 ml or 100 ml. 
Kartonska škatla z 1 brezbarvno stekleno injekcijsko vialo po 20 ml, 50 ml ali 100 ml. Ni nujno, da so v prometu vsa navedena pakiranja.
Carton for 20 ml, 50 ml, 100 ml and 250 ml 
PODATKI NA ZUNANJI OVOJNINI Škatla za 20 ml, 50 ml, 100 ml ali 250 ml vialo
Shelf-life of the veterinary medicinal product as packaged for sale: 30 months Shelf life after first opening the immediate packaging: 3 months. 
Rok uporabnosti zdravila v pakiranju za prodajo: 30 mesecev.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. 
Zaradi nevarnosti toksičnih učinkov na ledvice se dajanju zdravila izogibamo pri dehidriranih, hipovolemičnih ali hipotenzivnih živalih.
Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/25 kg body weight). 
Enkratna intramuskularna injekcija odmerka po 0,4 mg meloksikama na kilogram telesne mase (to je 2,0
Cattle: meat and offal: 15 days. 
Govedo: meso in organi: 15 dni Prašiči: meso in organi: 5 dni
Inflacam 1.5 mg/ml oral suspension for dogs Meloxicam 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Inflacam 1,5 mg/ml peroralna suspenzija za pse Meloksikam
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. 
Zdravljenje nadaljujemo z enim peroralnim,-vzdrževalnim odmerkom po 0,1 mg meloksikama na kilogram telesne mase na dan (v 24-urnih presledkih).
Dose scheme for the maintenance dose: 
DAJANJA ZDRAVILA Odmerjanje
In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically. 
Zelo redko se lahko pojavijo anafilaktoidne reakcije, ki so lahko resne (vključno s smrtnimi) in jih je treba zdraviti simptomatsko.
INDICATIONS 
ZDRAVILA
In this situation, you should inform your doctor as soon as possible. 
V tem primeru čim prej obvestite zdravnika.
Recommended wording 
Priporočeno besedilo
Avoid any unnecessary exercise as this might increase the risk of a tendon rupture. 
Izogibajte se kakršni koli nepotrebni vadbi, saj lahko poveča tveganje za pretrganje kite.
Before taking this medicine 
Preden boste vzeli to zdravilo
Therefore the following text should be added in Section 4.1 as relevant: 
Zato je treba v poglavju 4.1 dodati naslednje besedilo, kot je primerno:
Therefore, concomitant use of corticosteroids should be avoided. 
Sočasni uporabi kortikosteroidov se je zato treba izogibati.
Section 4.8: undesirable effects 
Poglavje 4.8: Neželeni učinki
Medically incorrect indications 
Medicinsko nepravilne indikacije
Should medicinal products no longer have any authorised indications with a positive benefit-risk balance then the national competent authorities should take the appropriate action in line with the conclusions on this procedure under Article 31 of Directive 2001/83/EC. 
Če zdravila nimajo več dovoljenih indikacij s pozitivnim razmerjem med koristmi in tveganji, morajo nacionalni pristojni organi sprejeti ustrezne ukrepe v skladu z zaključki tega postopka, ki je v skladu z 31. členom Direktive 2001/83/ES.
You and your doctor will decide on continuing the treatment considering also an antibiotic from another class. 
Skupaj z zdravnikom se boste odločili o nadaljnjem zdravljenju, morebiti tudi z antibiotikom iz kakšne druge skupine.
The product information may be subsequently updated by the Member State competent authorities, in liaison with the reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC. 
Informacije o zdravilu bodo morda pristojni organi držav članic v sodelovanju z referenčno državo članico kasneje posodobili, če je primerno, v skladu s postopki opredeljenimi v poglavju 4 naslova III Direktive 2001/83/ES.
Recommended wording of category 1 indications 
Priporočeno besedilo za indikacije kategorije 1
When taking this medicine 
Med jemanjem tega zdravila
The following new warning should be included at the beginning of the warning statements on safety issues: 
Naslednje novo opozorilo je treba vključiti na začetku opozorilnih stavkov o pomislekih glede varnosti:
Section 4.1: therapeutic indications 
Poglavje 4.1: Terapevtske indikacije
If this happens, stop taking <product name> and inform your doctor immediately in order to prevent the development of potentially irreversible condition. 
Če se to zgodi, prenehajte jemati zdravilo <ime zdravila> in o tem takoj obvestite zdravnika, da preprečite razvoj potencialno ireverzibilnega stanja.
Consideration should be given to official guidance on the appropriate use of antibacterial agents. 
Pri zdravljenju je treba upoštevati uradne smernice o pravilni uporabi protibakterijskih zdravil.
For systemically administered levofloxacin containing products the listing of risk factors within the first above mentioned sentence should additionally include “in patients receiving daily doses of 1000 mg levofloxacin”. 
Za sistemsko uporabljena zdravila, ki vsebujejo levofloksacin, mora navedba o dejavnikih tveganja v prvem zgoraj navedenem stavku dodatno vsebovati »pri bolnikih, ki prejemajo dnevne odmerke 1000 mg levofloksacina«.
Section 2 Warnings and precautions 
Poglavje 2: Opozorila in previdnostni ukrepi
Note: the indications are grouped under headings or cover terms that encompass the same medical entity; all changes apply to both the cover term and sub-headings, as relevant. 
Opomba: indikacije so združene pod naslovi ali skupnimi izrazi za enaka zdravstvena stanja; vse spremembe se nanašajo na oboje, na skupni izraz in podnaslove, kot je ustrezno.
Your risk is increased if you are elderly (above 60 years of age), have received an organ transplant, have kidney problems or if you are being treated with corticosteroids. 
Tveganje je povečano, če ste starejši (stari več kot 60 let), so vam presadili organ, imate težave z ledvicami ali se zdravite s kortikosteroidi.
Inflammation and ruptures of tendons may occur within the first 48 hours of treatment and even up to several months after stopping of <product name> therapy. 
Vnetje in pretrganja kit se lahko pojavijo že v prvih 48 urah zdravljenja, lahko pa tudi več mesecev po prenehanju zdravljenja z zdravilom <ime zdravila>.
These infections include cystitis, 
Te okužbe vključujejo cistitis,
• Sepsis due to above-mentioned genito-urinary infections 
• Sepsa zaradi zgoraj omenjenih genitourinarnih okužb
These amendments to the relevant sections of the product information are the outcome of the referral procedure. 
Te spremembe ustreznih poglavij informacij o zdravilu so bile dogovorjene v postopku napotitve.
In addition of the amendments recommended below, the following sentence should be included in all quinolones and fluoroquinolones containing medicinal products at the end of section 4.1: 
Poleg spodaj priporočenih sprememb je treba pri vseh zdravilih, ki vsebujejo kinolone in fluorokinolone, na koncu poglavja 4.1 vključiti naslednji stavek:
• Acute and chronic prostatitis, including severe forms 
• Akutni in kronični prostatitis, vključno s hudimi oblikami
The use of [INN] should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). 
Uporabi [INN] se je treba izogibati pri bolnikih, pri katerih so se v preteklosti med uporabo zdravil, ki vsebujejo kinolone ali fluorokinolone, pojavili resni neželeni učinki (glejte poglavje 4.8).
Tuberculosis, in combination treatment 
• Tuberkuloza, pri kombiniranem zdravljenju
The current warning statement on tendinopathies/tendon disorders should be amended with regard to risk factors, time to onset and need for monitoring of patients and should include at least the following information (or added as new statement if missing): 
Trenutni opozorilni stavek o tendinopatijah/poškodbah kit je treba popraviti glede dejavnikov tveganja, časa do pojava in potrebe po spremljanju bolnikov, in mora vključevati vsaj naslednje informacije (ali ga dodati kot novo besedilo, če manjka):
Corticosteroids should not be used if signs of tendinopathy occur. 
Če se pojavijo znaki tendinopatije, se ne sme uporabiti kortikosteroidov.
Prevention of infection in surgical procedures 
Preprečevanje okužb pri kirurških postopkih
Treatment of these patients with [INN] should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 
Zdravljenje teh bolnikov s/z [INN] se sme uvesti le v primeru, da ni drugih možnosti zdravljenja, in po skrbni oceni razmerja med koristmi in tveganji (glejte tudi poglavje 4.3).
If you experience any of these side effects after taking [Name of product], contact your doctor immediately prior to continuing treatment. 
Če se po jemanju zdravila [ime zdravila] pojavi kateri koli od teh neželenih učinkov, se takoj posvetujte z zdravnikom, preden nadaljujete z zdravljenjem.
The following warning should be included: 
Vključiti je treba naslednje opozorilo:
[INN] should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice. 
Zdravljenje z [INN] je treba prenehati takoj ob prvih znakih ali simptomih kakršnih koli resnih neželenih učinkov, bolniku pa je treba svetovati, naj se posvetuje z zdravnikom, ki mu je zdravilo predpisal.
Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of treatment. 
Tendinitis in ruptura kite (zlasti, a ne izključno, Ahilove tetive), včasih obojestransko, se lahko pojavita že v 48 urah po začetku zdravljenja s kinoloni in fluorokinoloni, o njiju pa so poročali tudi še več mesecev po prenehanju zdravljenja.
Section 4.4: special warnings and precautions for use 
Poglavje 4.4: Posebna opozorila in previdnostni ukrepi
Prolonged, disabling and potentially irreversible serious adverse drug reactions 
Dolgotrajni, onesposabljajoči in potencialno ireverzibilni resni neželeni učinki
At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with [INN] should be discontinued and alternative treatment should be considered. 
Ob prvem znaku tendinitisa (npr. boleča oteklina, vnetje) je treba zdravljenje s/z [INN] prenehati in razmisliti o drugačnem zdravljenju.
The risk of tendinitis and tendon rupture is increased in older patients, patients with renal impairment, patients with solid organ transplants, and those treated concurrently with corticosteroids. 
Tveganje za tendinitis in rupturo kite je povečano pri starejših bolnikih, bolnikih z okvaro ledvic, bolnikih s presajenimi organi in pri tistih, ki se sočasno zdravijo s kortikosteroidi.
An asterisk should be added to the title of selected SOCs as follows: Musculoskeletal and connective tissue disorders* Nervous system disorders* 
K naslovu izbranih organskih sistemov je treba dodati zvezdico, kot sledi: Bolezni mišično-skeletnega sistema in vezivnega tkiva* Bolezni živčevja*
The affected limb(s) should be appropriately treated (e.g. immobilisation). 
Prizadeto okončino ali okončine je treba ustrezno oskrbeti (npr. imobilizacija).
• Immunocompromised patients: o Infections in neutropenic patients (as prophylaxis). 
• Imunokompromitirani bolniki: o Okužbe pri nevtropeničnih bolnikih (kot profilaksa).
• Complicated intra-abdominal infections. 
• Zapletene intraabdominalne okužbe.
At the first sign of pain or inflammation of a tendon (for example in your ankle, wrist, elbow, shoulder or knee), stop taking <product name>, contact your doctor and rest the painful area. 
Ob prvem znaku bolečine ali vnetja kite (na primer v gležnju, zapestju, komolcu, rami ali kolenu) prenehajte jemati zdravilo <ime zdravila>, posvetujte se z zdravnikom in pustite, da prizadeti ud miruje.
The indications in the table below should be deleted for all quinolones/ fluoroquinolones containing products Pharyngitis-Tonsillitis 
Indikacije, ki so navedene v spodnji preglednici, je treba izbrisati pri vseh zdravilih, ki vsebujejo kinolone/fluorokinolone Faringitis - tonzilitis
The following new warning should be included: 
Vključiti je treba naslednje novo opozorilo:
• Bacterial prostatitis Children and adolescents 
• Bakterijski prostatitis Otroci in mladostniki
• Infection in immunocompromised patients 
• Okužbe pri imunokompromitiranih bolnikih
General disorders and administrative site conditions* Psychiatric disorders* 
Splošne težave in spremembe na mestu aplikacije* Psihiatrične motnje*
Infection of cerebrospinal fluid 
Okužba cerebrospinalne tekočine
• Acute sinusitis (last line) 
• Akutni sinusitis (zadnja izbira)
• Infections of bone and joints (osteomyelitis caused by gram-negative microorganisms) 
• Okužbe kosti in sklepov (osteomielitis, ki ga povzročajo gramnegativni mikroorganizmi)
The warning about peripheral neuropathies should be included/amended as follows: 
Vključiti/spremeniti je treba opozorilo o perifernih nevropatijah, kot sledi:
• Ciprofloxacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection 
• Ciprofloksacin se lahko uporablja za zdravljenje nevtropeničnih bolnikov s povišano telesno temperaturo, če obstaja sum, da je posledica bakterijske okužbe
• Alternative form of treatment for bone and joint infections 
• Alternativna oblika zdravljenja za okužbe kosti in sklepov
Nosocomial pneumonia 
Nozokomialna pljučnica
You should not take fluoroquinolone/quinolone antibacterial medicines, including [product name], if you have experienced any serious adverse reaction in the past when taking a quinolone or fluoroquinolone. 
Protibakterijskih zdravil, ki vsebujejo fluorokinolone/kinolone, vključno z zdravilom [ime zdravila], ne smete jemati, če so se vam pri jemanju fluorokinolonov ali kinolonov že kdaj pojavili kakršni koli resni neželeni učinki.
• Post-exposure prophylaxis and curative treatment of anthrax. 
• Profilaksa po izpostavljenosti in kurativno zdravljenje antraksa.
• Urethritis and cervicitis due to bacteria susceptible to fluoroquinolones 
• Uretritis in cervicitis zaradi bakterij, občutljivih na fluorokinolone
• Pelvic inflammatory disease, in combination with other antibacterial agents 
• Medenična vnetna bolezen, v kombinaciji z drugimi protibakterijskimi zdravili
Prolonged, disabling and potentially irreversible serious side effects Fluoroquinolone/quinolone antibacterial medicines, including [product name], have been associated with very rare but serious side effects, some of them being long lasting (continuing months or years), disabling or potentially irreversible. 
Dolgotrajni, onesposabljajoči, potencialno ireverzibilni resni neželeni učinki Protibakterijska zdravila, ki vsebujejo fluorokinolone/kinolone, vključno z zdravilom [ime zdravila], so bila povezana z zelo redkimi, a resnimi neželenimi učinki, od katerih so bili nekateri dolgotrajni (trajali so več mesecev ali let), onesposabljajoči ali potencialno ireverzibilni.
Annex III Amendments to relevant sections of the product information 
Spremembe, ki jih je treba vključiti v ustrezna poglavja informacij o zdravilu
• Gonorrhoea • Gonococcal urethritis in humans 
• Gonoreja • Gonokokni uretritis pri ljudeh
Ear, nose and throat infections o Ear, nose and throat infections (with the exception of acute tonsillitis) 
• Okužbe ušes, nosu in žrela o Okužbe ušes, nosu in žrela (z izjemo akutnega tonzilitisa)
• Salmonella infections (carrier) 
• Okužbe s salmonelo (nosilci okužbe)
• Pneumonia o Pneumonia, especially when caused by so-called "problematic" germs such as: E. coli, Klebsiella, Enterobacter, Proteus, Pseudomonas, Legionella or Staphylococcus o Pneumonia, above all if it's caused by bacteria such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Pseudomonas, Legionella or Staphylococcus 
• Pljučnica o Pljučnica, zlasti, če jo povzročajo tako imenovani »problematični« povzročitelji, kot so: E. coli, Klebsiella, Enterobacter, Proteus, Pseudomonas, Legionella ali Staphylococcus o Pljučnica, zlasti, če jo povzročajo bakterije, kot so Escherichia coli, Klebsiella, Enterobacter, Proteus, Pseudomonas, Legionella ali Staphylococcus
The indications in the table below should be restricted for all quinolones/ fluoroquinolones containing products in order to be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. 
Indikacije v spodnji preglednici je treba omejiti pri vseh zdravilih, ki vsebujejo kinolone/fluorokinolone, da bi se uporabljala samo, kadar je uporaba drugih protibakterijskih zdravil, ki se običajno priporočajo za zdravljenje teh okužb, neustrezna.
Patients under treatment with [INN] should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition. 
Bolnikom, ki se zdravijo s/z [INN], je treba svetovati, da morajo pred nadaljevanjem zdravljenja obvestiti zdravnika, če se pojavijo simptomi nevropatije, npr. bolečina, žarenje, mravljinčenje, odrevenelost ali šibkost, da se prepreči razvoj potencialno ireverzibilnega stanja (glejte poglavje 4.8).
• Pulmonary tuberculosis by resistant mycobacteria, especially in immunocompromised patients (minor anti-tuberculosis medicine) 
• Pljučna tuberkuloza, ki jo povzročajo odporne mikobakterije, predvsem pri imunokompromitiranih bolnikih (manj uporabljana zdravila proti tuberkulozi)
• Prevention of traveller's diarrhoea Preoperative preparations for chronic cholesteatomatous otitis and chronic otitis spreading to bone Septicaemia Selective decontamination of gastrointestinal tract in patients with compromised immune system Prevention of exacerbations in women with recurring urinary tract infections 
• Preprečevanje potovalne driske Predoperativna priprava za kronični holesteatomatozni otitis in kronični otitis, ki se je razširil na kost Septikemija Selektivna dekontaminacija prebavil pri bolnikih s kompromitiranim imunskim sistemom Preprečevanje poslabšanj pri ženskah s ponavljajočimi se okužbami sečil
• Prophylaxis of infectious gastroenteritis (traveller's diarrhoea) 
• Profilaksa infekcijskega gastroenteritisa (potovalne driske)
• Tonsillitis Laryngitis Acute bronchitis Prophylaxis of travellers´ diarrhoea 
• Tonzilitis Laringitis Akutni bronhitis Profilaksa potovalne driske
1.1 Deletion of indications 1.1.1 For all quinolones/fluoroquinolones 
1.1 Izbris indikacij 1.1.1 Za vse kinolone/fluorokinolone
• Complicated urinary tract infections (except complicated pyelonephritis) 
• Zapletene okužbe sečil (razen zapletenega pielonefritisa)
• Superinfection of chronic otitis (whatever its nature) and cavities after mastodectomy 
• Superinfekcija kroničnega otitisa (vseh vrst) in votlin po mastodektomiji
• Gastroenteritis o bacterial gastroenteritis o Gastroenteritis o Acute bacterial gastroenteritis o bacterial enteritis o Acute bacterial gastroenteritis after stool culture and laboratory confirmation of the susceptibility of the causative organism to NOROCIN 
• Gastroenteritis o Bakterijski gastroenteritis o Gastroenteritis o Akutni bakterijski gastroenteritis o Bakterijski enteritis o Akutni bakterijski gastroenteritis po kulturi blata in laboratorijski potrditvi občutljivosti povzročitelja na NOROCIN
• Inhalation anthrax: post-exposure prophylaxis and curative treatment 
• Inhalacijski vranični prisad: profilaksa po izpostavitvi povzročitelju in zdravljenje
Complicated skin and soft tissue infections / Complicated skin and skin structure infections 
Zapletene okužbe kože in mehkih tkiv/Zapletene okužbe kože in kožnih struktur
Gynaecological infections o Gynaecological infections 
• Ginekološke okužbe o Ginekološke okužbe
• Gonorrhoea o gonorrhoea o uncomplicated gonorrhea o Gonococcal urethritis, pharyngitis, proctitis or cervicitis from Neisseria gonorrhoeae irrespective of the production of penicillinase. 
• Gonoreja o Gonoreja o Nezapletena gonoreja o Gonokokni uretritis, faringitis, proktitis ali cervicitis zaradi Neisseria gonorrhoeae, ne glede na proizvodnjo penicilinaze.
pyelitis, 
pielitis,
A - Summary of product characteristics (SmPC) 
A - Povzetek glavnih značilnosti zdravila
• Prophylaxis after surgeries or interventions in the urogenital system o prophylaxis after surgeries or interventions in the urogenital system o Prophylaxis of recurrent urinary infections following trans-urethral surgery or trans rectal prostatic biopsy 
• Profilaksa po operacijah ali posegih v urogenitalnem sistemu o profilaksa po operacijah ali posegih v urogenitalnem sistemu o profilaksa ponavljajočih se okužb sečil po transuretralni operaciji ali transrektalni biopsiji prostate
1.2 Amendment of indications 1.2.1 For all quinolones/fluoroquinolones 
1.2 Sprememba indikacij 1.2.1 Vsi kinoloni/fluorokinoloni
Recommended wording o Urinary tract infections (acute or recurrent cystitis, acute uncomplicated pyelonephritis) 
Priporočeno besedilo o Okužbe sečil (akutni ali ponavljajoči se cistitis, akutni nezapleteni pielonefritis)
• Acute exacerbation of chronic bronchitis (last line) 
• Akutno poslabšanje kroničnega bronhitisa (zadnja izbira)
• Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa 
• Bronhopulmonalne okužbe pri cistični fibrozi, ki jih povzroča Pseudomonas aeruginosa
• Severe skin and soft-tissue infections (last line) 
• Hude okužbe kože in mehkih tkiv (zadnja izbira)
For quinolones and fluoroquinolones containing medicinal products, the existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below (new text underlined and in bold, deleted text strike through): 
Obstoječe informacije o zdravilih, ki vsebujejo kinolone in fluorokinolone, se spremenijo (z vstavljanjem, nadomeščanjem ali brisanjem besedila, kot je ustrezno) tako, da vsebujejo dogovorjeno besedilo, kot je navedeno spodaj (novo besedilo je podčrtano in krepko, izbrisano besedilo je prečrtano):
• Simple uncomplicated acute cystitis in the premenopausal adult women 
• Nezapleteni akutni cistitis pri odraslih ženskah pred menopavzo
• Treatment of ofloxacin sensitive prophylaxis of bacterial infections in patients with weakened resistance (for example neutropenic patients) 
• Profilaktično zdravljenje bakterijskih okužb z bakterijami, občutljivimi na ofloksacin, pri bolnikih z oslabljeno odpornostjo (na primer nevtropenični bolniki)
Section 4. 
Priloga III
• Bacterial gastroenteritis o Bacterial gastroenteritis o Bacterial enteritis o Intestinal infections o bacterial diarrhoea, which needs antibacterial treatment 
• Bakterijski gastroenteritis o Bakterijski gastroenteritis o Bakterijski enteritis o Okužbe črevesja o Bakterijska driska, ki jo je treba zdraviti s protibakterijskimi zdravili
Pain and swelling in the joints and inflammation or rupture of tendons may occur rarely. 
Redko se lahko pojavita bolečina in oteklina sklepov ter vnetje ali pretrganje kit.